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Abstract
One of the most relevant risk factors for hepatocellular carcinoma (HCC) development is chronic hepatitis B virus (HBV)
infection, but only a fraction of chronic HBV carriers develop HCC, indicating that complex interactions among viral,
environmental and genetic factors lead to HCC in HBV-infected patients. So far, host genetic factors have incompletely been
characterized. Therefore, we performed a genome-wide association (GWA) study in a Southern Chinese cohort consisting of
95 HBV-infected HCC patients (cases) and 97 HBV-infected patients without HCC (controls) using the Illumina Human610-
Quad BeadChips. The top single nucleotide polymorphisms (SNPs) were then validated in an independent cohort of 500
cases and 728 controls. 4 SNPs (rs12682266, rs7821974, rs2275959, rs1573266) at chromosome 8p12 showed consistent
a s s o c i a t i o ni nb o t ht h eG W Aa n dr e p l i c a t i o np h a s e s( O R combined=1.31–1.39; pcombined=2.71 610
25–5.19610
24;
PARcombined=26–31%). We found a 2.3-kb expressed sequence tag (EST) in the region using in-silico data mining and
verified the existence of the full-length EST experimentally. The expression level of the EST was significantly reduced in
human HCC tumors in comparison to the corresponding non-tumorous liver tissues (P,0.001). Results from sequence
analysis and in-vitro protein translation study suggest that the transcript might function as a long non-coding RNA. In
summary, our study suggests that variations at chromosome 8p12 may promote HCC in patients with HBV. Further
functional studies of this region may help understand HBV-associated hepatocarcinogenesis.
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Introduction
Approximately 400 million persons worldwide are chronically
infected with hepatitis B virus (HBV) [1,2]. Carriers of HBV are at
an increased risk of developing cirrhosis, hepatic decompensation,
and hepatocellular carcinoma (HCC) development, especially in
the endemic areas of Southeast Asia, China, and Sub-Saharan
Africa. The virus is one of the most relevant risk factors for HCC.
However, only a fraction (incidence rate between 33.5 and 2,632
per 100,000 person-years for men in different populations) of
chronic HBV carriers develops HCC. This indicates that complex
interactions among viral, environmental and genetic factors lead to
HCC in HBV-infected patients. So far, host genetic factors have
incompletely been characterized and only a few studies identified
genes potentially conferring genetic susceptibility to HBV-
associated HCC [3–9].
Genome-wide association (GWA) study has greatly contributed
to the identification of common genetic variants related to
common diseases [10]. This hypothesis-free approach allows the
discovery of novel genetic loci previously not thought to be
associated with the disease. A recent GWA study has reported
a susceptibility locus for HBV-related HCC at 1p36.22; it has
shown that genes situated at the proximal region were aberrantly
expressed in HCC tumors [11]. Since population substructure
exists among Chinese living in different geographical regions [12],
the use of a more homogeneous population may improve power
to detect new risk loci. Therefore, we performed a GWA study
in a Southern Chinese cohort consisting of 95 HBV-infected
HCC patients (cases) and 97 HBV-infected patients without
HCC (controls) using the Illumina Human610-Quad BeadChips.
The top single nucleotide polymorphisms (SNPs) were then
validated in an independent cohort of 500 cases and 728 controls.
Four SNPs (rs12682266, rs7821974, rs2275959, rs1573266) at
chromosome 8p12 showed consistent association in both the
GWA and replication phases (ORcombined=1.31–1.39; pcombined=
2.71610
25–5.19610
24; population attributable risk (PAR)combined
=26–31%). Using in-silico data mining, we found no gene but a
2.3 kb expressed sequence tag (EST) in the 8p12 region.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28798Expression analysis of the EST in HCC and adjacent non-
tumorous liver tissues was performed and in-vitro transcription
and translation analysis of the EST were also done to examine the
EST’s involvement in HCC development.
Materials and Methods
Patient Selection and Materials
All cases and controls were recruited at Queen Mary Hospital,
University of Hong Kong, and were ethnically Southern Chinese.
All cases were positive for the hepatitis B surface antigen (HBsAg)
and were examined physically for symptoms and signs of HCC
and cirrhosis. Progressed carriers with HCC were defined as
HBsAg carriers with a serum alpha-fetoprotein level above
400 ng/mL and typical computed tomography findings. Histo-
logical examinations using fine-needle aspiration performed under
ultrasonographic guidance were also used to define HCC tumors.
Informed signed consent was obtained from the study subjects
prior to peripheral blood collection. Ethical approval was obtained
from the Institutional Review Board.
Ninety-five cases and 97 age- and sex-matched controls were
recruited for genome-wide genotyping in 2007. Each control was 5
years older than the age of onset of his/her matched case to ensure
that he/she was not developing HCC in the past 5 years. The
mean 6 SD onset age of cases, defined as the age at first diagnosis
of HCC, was 50.667.3 years, while the mean 6 SD age of
controls was 55.667.3 years. Further recruitment of cases and
controls was performed in 2008–2010, resulting in a total of 500
cases and 728 controls for independent validation. The mean 6
SD onset age of these cases was 52.869.0 years and the mean 6
SD age of the controls was 57.6610.5 years. The male to female
ratio in both cases and controls were about 4:1. In the genome-
wide genotyping cohort, 13 (13.7%) of the cases and 3 (3.1%) of
the controls had cirrhosis; only one case and none of the controls
had HBV/HCV co-infection; 11 (11.6%) of the cases and one of
the controls had alcohol consumption more than 60 g per day;
none of the cases and 16 (16.5%) of the controls had antiviral
treatment (Lamivudine, Adefovir and both).
DNA Extraction
Peripheral blood samples collected in EDTA blood tubes were
processed for DNA extraction on the day of collection. QIAmp
Blood DNA Midi and Mini kits (Qiagen, Valencia, CA, USA)
were used as described in the manufacturer’s protocol. DNA was
verified by gel electrophoresis; DNA purity was assessed by OD
260/280 ratio; DNA concentration was determined by the Quant-
iT
TM PicoGreenH dsDNA reagent (Life Tech., Carlsbad, CA,
USA).
Genotyping and Statistical Analysis
Genome-wide genotyping was carried out at deCODE Genetics
(Reykjavik, Iceland) using the Illumina Human610-Quad Bead-
Chips. We excluded related samples by allele sharing analysis
using PLINK v1.05 [13], outlier samples by principal component
analysis using EIGENSOFT v2.0 [14] and poor quality samples
having call rates ,95%. We also excluded SNPs with minor allele
frequency (MAF) ,0.01 in both cases and controls, having call
rates ,95% in both cases and controls, and having Hardy-
Weinberg equilibrium P-value ,0.001 in controls. After quality
control, 192 samples (95 cases and 97 controls) and 485,072 SNPs
remained for the subsequent association analyses.
Phenotype-genotype association for each SNP was assessed
using logistic regression analysis adjusted for age and gender in




2]}, where p is the risk
allele frequency, assuming a multiplicative model. The most
significant SNPs were genotyped in an independent sample of 500
cases and 728 controls using Sequenom (Sequenom Inc., San
Diego, CA, USA) and were analyzed for association by chi-
squared test. Association results from the GWA and replication
studies were combined using inverse variance-weighted fixed
effects meta-analysis. Since a previously reported susceptibility
locus [11], rs17401966, was not present in the genotyping array,
genotyping of this SNP was determined separately by TaqMan
allelic discrimination assay (Life Tech) in the same cohort (357
cases and 354 controls) and was also analyzed for association by
chi-squared test.
59 and 39RACE
59 and 39RACE were performed according to the manufactur-
er’s instruction in the 59/39 RACE Kit 2
nd Generation (Roche
Diagnostics, Mannheim, Germany). Total RNA was extracted
from HepG2 cell lines using the Trizol reagent (Life Tech.). The
extracted total RNA was subjected to DNase I treatment using the
TURBO DNA-free kit (Applied Biosystems). For 59RACE, the
DNase I treated RNA was used as a template for first-strand cDNA
synthesis with SP1 primer 59-GAG GTG AAG ATC CTG TCA
AAG GT-39. The resulting products were then polyadenylated
using dATP and were subsequently amplified using the Oligo(dT)
primer and the SP2 primer 59-GAA CGC ACC AGA TAA GAT
CTG AG-39. Similar to 59RACE, the first-strand cDNA synthesis
in 39RACE was performed using the Oligo(dT)-anchor primer
(provided in the kit). The subsequent PCR amplification was
carried out using a PCR anchor primer (provided in the kit) and
the SP5 primer 59-AAT AGC TTA ACC CTT TCA TTT ACC
A-39. The resulting products from 59 and 39RACE were cloned
into a pGEM-T Easy Vector (Promega, Madison, WI, USA) and
verified using DNA sequencing.
Quantitative PCR (qPCR) and Quantitative Expression
Analysis
The expression level of the EST transcript was examined in 40
pairs of HCC tumors and adjacent non-tumorous tissues using
relative qPCR with transcript specific primers as shown below.
Total RNA was extracted from the tissues using Trizol reagent
(Life Tech.). Complementary DNA was synthesized from 1 mgo f
total RNAs using MultiScribe
TM Reverse Transcriptase and
Oligo(dT) (Life Tech.) in which total RNA was treated with
TURBO DNA-free to remove possible DNA contamination. Each
qPCR reaction consisted of a 16FastStart SYBR Green I reaction
mixture (Roche Diagnostics), 500 nM of each forward (CTC AGA
TCT TAT CTG GTG CGT TC) and reverse (GAG GTG AAG
ATC CTG TCA AAG GT) primer, and 1 mL of synthesized
cDNA. The expression of a housekeeping gene of GAPDH was
examined and used for normalizing the expression of the EST
wild-type transcript. The expression level of the EST between the
HCC tumors and corresponding non-tumorous liver tissues was
examined using a non-parametric paired t-test, in which P,0.05
was considered significant.
Translation of FLAG-tagged EST Open Reading Fframe
(ORF)
The predicted largest ORF (encoding 94 amino acids) of the
EST transcript was amplified using the following sets of primers:
for N-terminal FLAG-tagged EST ORF, forward 59- CGC GAA
TTC ATG GAC TAC AAA GAC GAT GAC GAC AAG CTT
ATG AAA TAT AAT CAA GCA ATT AAC-39 and reverse 59-
GWAS Analysis of HBV Associated HCC Patients
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G-39; for C-terminal FLAG-tagged EST ORF, forward 59- CGC
GAA TTC ATG AAA TAT AAT CAA GCA ATT AAC-39 and
reverse 59- CGC GGA TCC TCA AAG CTT GTC GTC ATC
GTC TTT GTA GTC GAG AGA GGT GAA GAT CCT GTC
AAA G-39. The respective resulting amplicons were cloned into a
lentiviral expression vector, pCDH-CMV-EF1-GFP-Puro (SBI
System Biosciences, Mountain View, CA, USA) at the cloning sites
of EcoRI and BamHI. The N- and C-terminal FLAG-tagged
lentiviral expression plasmids were packaged into the lentiviruses
which were then transduced to the HepG2 cell line as described
previously [15]. Mock transduction using the empty vector was
run in parallel. The transduced HepG2 cells were lysed in NET
Buffer. The lysates were then resolved via 12% SDS-PAGE gel
electrophoresis and blotted onto nitrocellulose membrane. The
membrane was incubated with mouse anti-FLAG primary
antibody, followed by incubation with anti-mouse immunoglob-
ulin G (GE Healthcare, Buckinghamshire, UK), and was then
detected using ECL plus Western blotting detection system (GE
Healthcare) according to the manufacturer’s protocol. Detection
of endogenous b-actin was performed as for protein loading
control.
Results
GWA and replication studies suggest that the 8p12
region contains susceptibility locus for HBV-related HCC
In the GWA study, there was no SNP reaching genome wide
significance (p=5610
28). As shown in Figure 1, the strongest
association signal was seen in the intergenic region at chromosome
8 (8p12; p=6.35610
26) driven by rs2275959. The association
signal from this SNP was supported by associations from nearby
SNPs (rs12682266, rs7821974, rs1573266) in linkage disequilibri-
um (LD) (Table 1), indicating that the signal was likely to be real.
In contrast, the next strongest signal located on chromosome
11p13 (rs2611145, p=9.31610
26) had no other SNP in the
region which show similar levels of association, indicating that it
was likely to be a false positive result. We then genotyped the 4
SNPs in the 8p12 region in an independent sample (500 cases and
728 controls). The risk alleles of these SNPs were the same as in
the GWA study (Table 1), but the combined analysis of the GWA
study and replication samples revealed only suggestive associations




The SNP rs17401996 was not associated with HBV-related
HCC susceptibility
To test whether a previously reported susceptibility locus [11],
rs17401996, was associated with HBV-related HCC susceptibility
in our samples, we also genotyped the SNP in 357 HBV-positive
HCC cases and 354 HBV-positive non-HCC controls using
TaqMan allelic discrimination assay. We found no significant
difference (p=0.91) in allele frequencies between cases and
controls (71.1% in cases versus 71.4% in controls).
In Silico Data Mining Identified EST at 8p12
Results of in silico data mining (Figure S1) showed that there are
no genes in the 8p12 region; however, an EST was identified
within the studied haplotype block and encompasses the
rs2275959 and rs2298321 SNPs, which were located in the
HCC risk-associated haplotype block found in GWA. More
notably, this EST was expressed in the HepG2 hepatoma cell line,
and it was also detected in other human tissue types, such as
prostate, intestine, placenta, and testis, according to the Stanford
SOURCE database. The results of an ENCODE Histone
Modification ChIP-Seq study on a panel of human cell lines
(Figure S1) revealed that the chromatin region harboring the EST,
particularly in the HepG2 cell line, had a remarkably high level of
histone 3 lysine-4 methylation and acetylation as compared to the
other examined cell lines. This result indicates that the EST may
be actively expressed in this cell line. In fact, the expression of this
transcript was detected by RT-PCR in various HCC cell lines,
including HepG2, HLE, Huh7, BEL-7402, and PLC/PRF/5
(data not shown).
Figure 1. Manhattan plot of GWA study results of testing for association with HBV-related HCC susceptibility. The dotted line indicates
the p-value threshold of 1610
25. The circled SNPs are those passing the threshold (Table 1).
doi:10.1371/journal.pone.0028798.g001
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We confirmed the full-length sequence of the EST transcript
(2.3 kb) and demonstrated that the 39 end of the transcript was
polyadenylated by 59/39RACE. The 2.3 kb transcript is intronless
as reported (GenBank:AK025743). Primers designed to specifically
detect the transcript were used to quantify the relative expression
level of this transcript and revealed that its expression level was
significantly reduced in HBV-associated HCC tumors, as compared
to the corresponding non-tumorous liver tissues (P,0.001,
Figure 2A). Based on the possibility that the transcript could encode
a protein, we performed a sequence analysis of the hypothetical
protein product of the transcript, LOC157860, using InterProScan,
which indicates that the protein sequence possesses a signal-peptide
sequence and a transmembrane region in the N-terminal half of the
sequence. Despite the2.3 kb lengthof thetranscript, only very short
open reading frames (ORF) were predicted. The largest ORF
encodes only 94 amino acids while the three other predicted ORFs
encode 54, 55, and 67 amino acids, respectively. We then stably
transduced HepG2 cells with expression plasmids containing either
N-terminal or C-terminal FLAG-tagged ORF (encoding 94 amino
acids) (Figure 2B). The C-terminal FLAG-tagged EST ORF was
detected by anti-FLAG immunoblotting in the transduced HepG2
cell lysate and had the expected size in the immunoblotting results,
but the N-terminal FLAG-tagged one was not translated in its
corresponding cell lysate (Figure 2B). We therefore propose that the
transcript might act as a large intervening ncRNA, but further
investigation is needed.
Discussion
In this study, we identified a new candidate susceptibility locus
on chromosome 8p12 for HBV-associated HCC in Southern
Chinese using GWA study. In-silico data mining showed that an
EST and its transcript isoforms are situated in this region. The full
length of the transcript was verified by 59and 39RACE and DNA
sequencing. The region contained high levels of chromatin
activation marks (UCSC Browser), which was additionally
observed in the hepatoma cell line HepG2, indicating transcrip-
tional activation. A comparative genomic analysis indicates that
the transcript region is evolutionarily conserved in mammals
(Figure S2) and suggests that this region may be of some functional
importance.
Previous reports investigating the loss of heterozygosity and
comparative genomic hybridization have shown that region 8p
was one of the most frequently deleted regions in HCCs, as
demonstrated by our previous study [16] and other studies [17].
Notably, the well-known liver cancer suppressor gene, Deleted in
Liver Cancer 1 (DLC1),[18] is also situated on chromosome arm
8p. It spans over the region of p21.3–22 and is about 24 Mb
upstream of the four 8p12 SNPs. We speculate that risk-associated
8p12 SNPs or haplotypes might have an interacting effect on the
DLC1 locus, causing DLC1 more susceptible to deletion or
chromosomal loss; however, the underlying mechanism of such
effect remains to be investigated.
In this study, we confirmed the full-length sequence of the EST
transcript (2.3 kb) and demonstrated that the 39 end of the
transcript was polyadenylated by 59/39RACE. The expression
level of this transcript was significantly reduced in HBV-associated
HCC tumors, as compared to non-tumorous liver tissues.
Significantly, the transcript was also detected in other HCC cell
lines, specifically HLE, Huh7, BEL-7402, and PLC/PRF/5.
Despite the 2.3 kb length of the transcript, only very short ORFs
were predicted, with the largest encoding only 94 amino acids.
The C-terminal FLAG-tagged ORF was detected by anti-FLAG
immunoblotting in the transduced HepG2 clones, but its N-
terminal FLAG-tagged one was not expressed. The evidence is
consistent with the characteristics of ncRNAs suggested by Panzitt
et al.[19] We therefore propose that the transcript might act as
long ncRNAs, but further investigation is required. Moreover, it
remains to be investigated whether the reduction in expression is
limited to HCCs. ncRNAs are a class of molecules that play
regulatory roles in cells. Notably, several ncRNAs are implicated
in human cancers. In contrast to proteins that are encoded by
coding RNAs, the function of ncRNAs cannot currently be
inferred from their sequence or structure. A large intervening
ncRNA (lincRNA), which can range from 200 nt to .100 kb, can
be intergenic, intronic, antisense or overlapping with protein-
coding genes or other ncRNAs [20,21]. The known repertoire of
lincRNA functions is still being unveiled with roles as mediator of
mRNA decay [22], structural scaffolds for nuclear substructures
[23], and as regulators of chromatin remodeling [24]. For
instance, the HOTAIR lincRNA was reported to be overexpressed
in breast tumors and found to be a significant predictor of
metastasis and death [25]. Functional analyses revealed that
HOTAIR silences the HOXD locus in trans by inducing a repressive
chromatin state. Similarly, overexpression of the nuclear speckle
associated lincRNA metastasis-associated lung adenocarcinoma
transcript 1 (MALAT1) modulates alternative splicing. It was found
associated with metastasis and poor outcome in patients with lung
cancer [26]. Another recent report also identified and demon-
strated that the HULC long ncRNA is differentially expressed in
HCC tumors [19].






















controls OR P-value PAR
8 rs12682266 37548149 G/A 0.64 0.41 2.55 6.69610
26 0.55 0.49 1.25 7.10610
23 0.56 0.48 1.38 3.76610
25 0.285
8 rs7821974 37569159 T/C 0.62 0.39 2.54 7.01610
26 0.54 0.49 1.20 2.61610
22 0.55 0.48 1.33 2.32610
24 0.255
8 rs2275959 37574217 T/C 0.54 0.31 2.59 6.35610
26 0.46 0.42 1.18 4.75610
22 0.47 0.41 1.31 5.19610
24 0.213
8 rs1573266 37581577 C/T 0.69 0.47 2.58 7.44610
26 0.59 0.54 1.26 5.20610
23 0.61 0.53 1.39 2.71610
25 0.313
11 rs2611145 34240437 T/C 0.52 0.29 2.56 9.31610
26 -- - - -- - - -
Chr, chromosome; RAF, risk allele frequency; OR, odds ratio.
aBased on NCBI build 36.
doi:10.1371/journal.pone.0028798.t001
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GWA study of HBV-related HCC susceptibility in Chinese and
the largest in Southern Chinese, but no SNP achieved genome-
wide significance (p,5610
28). Power should be an important
factor that influences the outcome of our current study. Our GWA
study and combined samples had 0.004% and 6.65% power,
respectively, for an OR of 1.35, assuming a disease prevalence of
0.65% and a 50% MAF. It is estimated that at least 1,700 cases
and an equal number of controls are required to achieve a power
of 80%. So, increasing sample size is one of the options to greatly
improve the power of our study. However, by adopting a less
stringent significant threshold of P,1610
25 which had recently
been used in another large scale GWA study [27], and after
demonstrating the consistent association in the validation sample
set and illustrating the in-vivo finding of reduction of the 8p12
EST expression in HCC, we speculated the 8p12 region is a new
HBV-associated HCC susceptible locus. Nevertheless, we could
not exclude the possibility that additional common genetic variants
with similar effect to those 8p12 SNPs exist.
In our study population, a previously reported susceptibility
locus at 1p36.22 [11], rs17401966, was not significantly associated
with HBV-related HCC. We had 80%, 60% and 34% power,
respectively, for an OR of 1.4, 1.3 and 1.2, assuming a disease
prevalence of 0.65% and a 30% MAF. So, sample size is unlikely
to be the major drawback for studying the rs17401966 SNP in our
cohorts. There might be some other confounding genetic factors,
which are different from our Southern Chinese cohorts,
interplaying with the risk associated 1p36.22 locus, hence
contributing to the development of HCC. It has recently
demonstrated that Han Chinese populations indeed exit of
different genetic structures [12]. Comparing the Guangdong
cohorts used in Zhang et al and our cohorts genotyped for the
rs17401966 SNP, there is a great evidence of heterogeneity with
Phet=0.035 by test of heterogeneity (Chi-square, 1df, 2-tailed)
although Hong Kong is situated closed to the Guangdong
province. The degree of heterogeneity is even greater when
comparing ours to the Northern Chinese Beijing cohorts
(Phet=0.0017). Owing to these genetic difference among Chinese
Figure 2. Expression of the EST in human HCCs and cell line. (A) Quantitative expression analysis of the EST transcript in the HBV-associated
HCCs showed that the EST transcript was significantly under-expressed in HCC tumors when compared with the corresponding non-tumorous livers
(P,0.0001, non-parametric paired t-test). Dots: the ratio of expression level of the transcript versus the level of GAPDH in each testing sample.
Horizontal lines: mean of the relative expression level in the HCC tumors and non-tumorous livers. (B) Left panel: Schematic diagram of the FLAG-
tagged expression constructs. Right panel: Western blot analysis of FLAG-tagged EST translation in HepG2 cell line. The FLAG-tag could be translated
only when tagged at the N-terminus of the ORF but not at the C-terminus. b-actin served as a loading control. EV: empty vector, FLAG-ORF: N-
terminal FLAG-tagged ORF, ORF-FLAG: C-terminal FLAG-tagged ORF.
doi:10.1371/journal.pone.0028798.g002
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apart from those non-genetic factors, can be used for HCC risk
assessment and disease management. The joint effect of genes in
contributing to cancer risk supports polygenic model. Polygenic
risk score assessed by providing genotyping results of some genetic
variants/SNPs has been reported to provide better risk prediction
for other hunan cancers, such as prostate [28] and breast cancers
[29].
Overall, we identified a HBV-associated HCC susceptibility
locus, which harbors an EST whose expression is significantly
associated with HBV-associated HCC development. Further
validation using a larger sample size and/or multiple populations,
particularly in Chinese patients, is helpful to substantiate our
findings. The functions of this EST transcript should also be
investigated.
Supporting Information
Figure S1 Computational data retrieval from the UCSC
Genome browser database on the human 8p12 region
(chr8:37,560,000–37,600,000 on Human NCBI36/hg18
assembly). The location of the EST transcript (GeneBank:
AK025743) is indicated by the black bar (chr8:37,574,170–
37,576,534). The histone 3 methylation and acetylation marks
(H3K4me1, H3K27Ac, and H3K4me3) are indicated by the
colored peaks; each color represents the results of one type of
human cell line, such as H1 ES, HMEC, HSMM, HUVEC,
K562, NHEK, NHLF, and HepG2. The H3K27Ac and
H3K4Me3 marks are particularly high in HepG2, as indicated
by the light green peaks.
(TIF)
Figure S2 DNA conserved region analysis in mammals.
Conserved regions are highlighted with shaded colored bars.
(TIF)
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